

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Title: PATENT APPLICATION of  
Inventor(s) SHERMAN, et al.

Appln. No.: 09/544,108

Group Art Unit: 1648

Filed: April 6, 2000

Examiner: WortmanT.

Title: COMPOSITION AND METHOD OF TREATING HEPATITIS C

# 41A  
2/6/02  
RECEIVED  
FEB 04 2002  
TECH CENTER 1600/2900

AMENDMENT

Hon. Commissioner of Patents  
and Trademarks  
Washington, DC 20231

Sir:

Responsive to the Office Action dated June 29, 2001, please enter the following amendments and consider the following remarks.

IN THE SPECIFICATION

**On page 6, please rewrite lines 1-9 as follows:**

ai x  
Inflammation. However, relapse within six months after the completion of treatment occurred in 51% of the patients treated with 3MU of interferon and in 44% of those treated with 1MU. Davis, G.L., et al., New England Journal of Medicine, 321:1501-06 (1989). These authors concluded that a 24-week course of interferon therapy is effective in controlling disease activity in many patients with hepatitis C, although relapse after the cessation of treatment is common.

**On page 7, please rewrite lines 14-19 as follows:**


a2  
It is clear, therefore, that while  $\alpha$ -interferon has beneficial effect on the course of HCV infection, this effect is frequently only transient. Therefore, new modalities are necessary in order permanently to eradicate the effects of hepatitis C virus on the patient.

1648/14

<b>AMENDMENT TRANSMITTAL LETTER (Large Entity)</b>		Docket No.	
Applicant(s): <b>Sherman</b>		Army 160	

Serial No. <b>09/544,108</b>	Filing Date <b>April 6, 2000</b>	Examiner <b>Wortman, D.</b>	Group Art Unit <b>1648</b>
---------------------------------	-------------------------------------	--------------------------------	-------------------------------

Invention: **Composition and Method of Treating Hepatitis C**




RECEIVED  
FEB 04 2002  
TECH CENTER 1600/2900

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Transmitted herewith is an amendment in the above-identified application.  
The fee has been calculated and is transmitted as shown below.


CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	21 -	24 =	0 x	\$18.00	\$0.00
INDEP. CLAIMS	3 -	3 =	0 x	\$84.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00

- ☐ No additional fee is required for amendment.
- ☒ Please charge Deposit Account No. **21-0380** in the amount of **\$920.00** (see pet. for ext. time)  
A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \_\_\_\_\_ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. **21-0380**  
A duplicate copy of this sheet is enclosed.
  - ☒ Any additional filing fees required under 37 C.F.R. 1.16.
  - ☐ Any patent application processing fees under 37 CFR 1.17.

  
Signature

Dated: **December 12, 2001**

**Caroline Nash, Reg. No. 36,329**  
**Nash & Titus, LLC**  
**3415 Brookeville Road**  
**Brookeville, MD 20833**  
**301 924-9500**  
**for: Elizabeth Arwine, REG No. 45,867**  
**U.S. Army Medical Research and Materiel Command**  
**Fort Detrick, MD 21702-9223**

I certify that this document and fee is being deposited <b>December 12, 2001</b> with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.
 Signature of Person Mailing Correspondence
<b>Caroline Nash</b> Typed or Printed Name of Person Mailing Correspondence

cc: